Blood Reviews
Volume 20, Issue 3 , Pages 173-178, May 2006

Duration of anticoagulation: decision making based on absolute risk

  • David Keeling

      Affiliations

    • Corresponding Author InformationTel.: +44 1865 225318; fax: +44 1865 225608.

Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, Oxford. OX3 7LJ, United Kingdom

published online 08 November 2005.

Summary 

We are often faced with the question as to the optimum duration of secondary prophylaxis with oral anticoagulants after an episode of venous thromboembolism. Theoretically if we know the recurrence rate, the case-fatality, the effectiveness of oral anticoagulant therapy, and the rate of fatal haemorrhage on treatment, we can calculate whether being on or off treatment is safest. Using these data and considering only the risk of death we would treat idiopathic deep vein thrombosis for six months. For those with DVT associated with a transient risk factor it would be reasonable to stop treatment after 3 months in those over 50 years old and we should certainly stop after 3 months in those over 70 years old. There are data to suggest that pulmonary embolism may have a higher case-fatality than deep vein thrombosis if there is a recurrence. If these data were accepted most patients with idiopathic pulmonary embolism would get long-term treatment. We can use these models to modify our assessment if other factors such as antiphospholipid antibodies or cancer are present.

Keywords: Venous thromboembolism, Anticoagulation, Duration

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0268-960X(05)00044-5

doi:10.1016/j.blre.2005.09.001

Blood Reviews
Volume 20, Issue 3 , Pages 173-178, May 2006